Figure 1.

Overview of proposed treatment algorithms involving combinatorial approaches for patients with advanced melanoma.

Dabra – dabrafenib / Tram – trametinib / Vem – vemurafenib / Cobi – cobimetinib / Enco – encorafenib / Bini – binimetinib / Ipi/Nivo – ipilimumab 3mk/kg + nivolumab 1mg/kg / “low-dose”- ipilimumab 1mg/kg + nivolumab 3mg/kg / * - for patients with symptomatic CNS metastases or using steroids, the optimal approach remains unclear / ** - in these scenarios, single-agent anti-PD-1 is also an acceptable alternative, particularly in select situations (underlying autoimmune diseases, comorbidities, etc.)